GAMMA Investing’s Standard BioTools LAB Stock Holding History

GAMMA Investing’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$222	Buy	+270	New	+$255	﹤0.01%	4080
2026 Q1	–	Sell	-735	Closed	-$941	–	4184
2025 Q4	$941	Buy	+735	New	+$987	﹤0.01%	3805

Other funds holding LAB

MAM

Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

GAMMA Investing's LAB Position: Q2 2026 in Review

GAMMA Investing opened a new position in Standard BioTools (LAB) in Q2 2026: 270 shares worth $222. The stake represents ﹤0.01% of the portfolio and ranks #4080 among its holdings. This is a return to the name: GAMMA Investing previously reported a position in LAB as recently as Q4 2025.

GAMMA Investing first reported a position in LAB in Q4 2025 and has held it in 2 quarters since. The position peaked at $941 in Q4 2025. 5 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

GAMMA Investing held 270 shares of Standard BioTools worth $222 as of Q2 2026.
Standard BioTools was a new GAMMA Investing position in Q2 2026.
Standard BioTools made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #4080 holding.
GAMMA Investing first reported a position in Standard BioTools in Q4 2025 and has held it in 2 quarters since.
GAMMA Investing's Standard BioTools position peaked at $941 in Q4 2025.
5 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.